LATEST NEWS: Mr. Gus Gazzard publishes ground-breaking research
On March 9th, the prestigious medical journal The Lancet published results from a pioneering research study, funded by the National Institute of Health Research (NIHR) and led by Gus Gazzard, consultant ophthalmologist and Glaucoma Service Director at Moorfields Eye Hospital.
The results of the three-year trial showed that using laser-based treatment on newly diagnosed cases of glaucoma was more successful and more cost-effective than the current method of using intraocular pressure lowering eye drops. There was also less need for treatment to be escalated and there was a reduced need for both glaucoma surgery and cataract extractions compared with patients who received the eye drops.
The results could potentially improve the way glaucoma is treated across the world and, if the treatment proves to be as effective with patients who have had the condition for some time, could save the NHS hundreds of millions of pounds a year.
Gus Gazzard reflects on his pioneering glaucoma research in the following video:
Mr. Gazzard is the author of this definitive review of the data on the main treatment for angle closure glaucoma. You can read more about his ground-breaking research here
Mr. Gazzard has recently been appointed Director of the Glaucoma Service at Moorfields Eye Hospital in London.
Mr. Gazzard has been awarded the prestigious, competitively awarded “NHS National Bronze Merit Award”. These awards recognise NHS consultants who perform ‘over and above’ the standard expected of their role.
Mr. Gazzard is now one of only three surgeons performing the innovative Hydrus stent procedure in the UK. You can read more about the Hydrus procedure here or you can download a PDF about Hydrus here.
NICE (National Institute for Health and Care Excellence) have released a report on Trabecular stent bypass microsurgery for open-angle glaucoma. You can read the full, positive report here.